In this study, we showed that the combination of a CXCR4 antagonist, POL5551, and a VEGF inhibitor, mcr84, can increase median overall survival in GBM xenografts compared to treatment with either drug as monotherapy. This evidence concerns the gene CXCR4 and glioblastoma.